Kolon Life Science to ship first supply of ‘Invossa’ to Hong Kong and Macao

Published: 2018-08-27 17:37:26

Updated: 2018-08-27 17:37:26

Kolon Life Science(CEO Woo-Seok Lee) announced to ship the first supply of the knee arthritis gene therapy ‘INVOSSA-K’ to Hong Kong and Macao.

This shipment is the first supply to Hong Kong and Macao after the agreement with Zhongji 1 International Medical Group on 20 June. The company agreed to exclusively supply the amount worth of KRW 17 billion at least with Zhongji, and the term will expi...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.